Summary of the Conference Call for China Traditional Chinese Medicine (CTCM) Company Overview - **Company**: China Traditional Chinese Medicine (CTCM) - **Fiscal Year**: 2025 - **Key Financials**: - Net loss attributable to shareholders: CNY 342 million - Net profit margin: -3.1% - Revenue: CNY 14.745 billion (down 10.7% YoY) - Total assets: CNY 32.347 billion (down 7.7% YoY) - Total liabilities: CNY 9.32 billion (down 16.3% YoY) [2][3][10] Industry Insights - **Market Dynamics**: - The Chinese herbal medicine industry is facing increased competition and pressure from centralized procurement policies. - The market for traditional Chinese medicine (TCM) is undergoing significant changes, with a focus on quality and integration across the supply chain [15][21]. Key Business Segments Performance 1. **Chinese Herbal Medicine Granules**: - Revenue: CNY 6.098 billion (down 12.5% YoY) - Gross margin: 53.8% (down 3.1 percentage points) - Impacted by increased competition and a higher proportion of centralized procurement [2][8]. 2. **Chinese Herbal Pieces**: - Revenue: CNY 3.334 billion (up 0.6% YoY) - Gross margin: 25.1% (up 1.9 percentage points) - Growth attributed to optimized sales structure and reduced procurement costs [2][8]. 3. **Traditional Chinese Medicine (TCM)**: - Revenue: CNY 4.248 billion (down 6.7% YoY) - Gross margin: 66.7% (up 3.1 percentage points) - Growth in prescription drugs and the launch of an e-commerce strategy for OTC products [2][9]. 4. **Health and Wellness Sector**: - Revenue: CNY 235 million (down 17.2% YoY) - Gross margin: 31.9% (up 7.5 percentage points) - Decline due to strategic withdrawal from low-efficiency product lines [9]. Strategic Initiatives - **2026 Strategy**: Focus on "stability, integration, and efficiency" to manage costs and enhance supply chain management [11][12]. - **Supply Chain Management**: Emphasis on strategic reserves of bulk medicinal materials and graded processing to control costs [13]. - **Digital Transformation**: Development of a data platform for full-chain management of TCM production, aiming for enhanced traceability and quality control [14][19]. Research and Development - **Innovation**: - 207 patents granted in 2025, including 126 invention patents. - Participation in drafting 57% of the national standards for herbal granules [6][7]. - **Clinical Research**: Focus on evidence-based medicine to enhance product lifecycle and efficacy [16][17]. Financial Health - **Debt Management**: Debt ratio reduced to 11.8% (down 6.7 percentage points) with cash reserves of CNY 4.045 billion [10]. - **Accounts Receivable**: Increased by 4.6% due to tight healthcare funding, with 50.4% of receivables aged under 90 days [10]. Future Outlook - **Market Conditions**: Anticipated continued pressure on the herbal granules segment due to ongoing centralized procurement policies [21]. - **Growth Expectations**: The company aims for stable revenue and profit in 2026, with a focus on transforming the herbal granules business and strengthening core segments [18][21]. Conclusion CTCM is navigating a challenging environment marked by regulatory changes and competitive pressures. The company is strategically positioned to leverage its R&D capabilities and supply chain management to enhance its market position while focusing on digital transformation and quality improvement initiatives.

Summary of Key Points Core Viewpoint - The company reported strong financial performance for 2025, with significant increases in revenue and net profit, indicating effective marketing reforms and recovery in profitability [4]. Financial Performance - The company achieved operating revenue of 925 million, net profit attributable to shareholders of 82 million, and net profit excluding non-recurring items of 80 million, representing year-on-year increases of 34.4%, 298.5%, and 328.9% respectively [4]. - Operating cash flow reached 244 million, up 1182% year-on-year, with basic EPS at 0.16 yuan [4]. - A cash dividend of 1.5 yuan per 10 shares was proposed, with total cash dividends and share buybacks accounting for 100.74% of the net profit for 2025 [4]. Marketing and Sales Strategy - The company has been implementing ongoing marketing reforms, leading to a steady recovery in sales revenue [5]. - The OTC product line has shifted to a mixed model of self-operated and promotional service providers, with an expanding self-operated team and broader regional coverage [5]. - The cough remedy product saw sales of 636 million pieces, recovering to 63.10% of the same period in 2023, contributing to a strong recovery in profitability [5]. Business Segment Performance - In 2025, revenue from the pharmaceutical industry increased by 35.21%, while pharmaceutical commerce remained stable with a slight decline of 0.03% [6]. - Revenue from traditional Chinese medicine doubled, driven by increased sales of the cough remedy, while chemical drug formulations experienced a decline due to reduced downstream demand [6]. - The company invested 260 million in brand building, a year-on-year increase of 107.7%, enhancing brand recognition, particularly among younger consumers [6].

Group 1 - The article discusses the applicability of the 9% VAT rate on various agricultural products, confirming that items like noodles and medicinal herbs fall under this category [4][6] - It clarifies that traditional Chinese medicine does not qualify for the 9% VAT rate, as it is not classified as an agricultural product [6] - Animal excrement is also excluded from the agricultural product category for the 9% VAT rate [8] Group 2 - The article outlines a tax exemption policy for small-scale taxpayers, stating that those with monthly sales below 100,000 yuan are exempt from VAT [14] - It mentions that small-scale taxpayers can benefit from a reduced VAT rate of 1% instead of the standard 3% [14]

Core Viewpoint - TE HEALTHCARE has entered into a conditional acquisition agreement to purchase 100% of the shares of Top Eminent II Limited for HKD 100.3 million, which will integrate the financial performance of the acquired entity into the group's consolidated financial statements [1]. Group 1: Acquisition Details - The acquisition agreement was signed on February 26, 2026, with Top Eminent I Limited as the seller [1]. - The target company, Top Eminent II Limited, is an investment holding company registered in the British Virgin Islands in 2015 [3]. - The acquisition will result in the target company becoming an indirect subsidiary of TE HEALTHCARE [2]. Group 2: Business Operations - The target group primarily engages in cross-border e-commerce, focusing on online sales and distribution of health and wellness products in Hong Kong and China [3]. - The group also operates internet medical services and internet hospitals in China, providing online medical consultations and related value-added health management services [3]. - The foreign-owned enterprise, Shenzhen Beijing Tongrentang International Network Technology Co., Ltd., is a wholly-owned subsidiary of the Hong Kong company and is responsible for executing the contractual arrangements with the combined entities [2].

Investment Rating - The industry investment rating for the pharmaceutical and biotechnology sector is "Hold" [2]. Core Insights - The report highlights the approval of Novartis' siRNA lipid-lowering drug for new indications in China, emphasizing the focus on the PCSK9 and small nucleic acid sectors [3]. - Mergers and acquisitions, along with licensing collaborations, remain active, accelerating resource integration in the innovative drug field [3]. - The development of brain-computer interfaces is entering a fast track, with the industrialization process accelerating [3]. - The Chinese herbal medicine industry is expected to experience a recovery in performance, with a focus on high-quality development [3]. Summary by Relevant Sections Industry Development - The Ministry of Industry and Information Technology and seven other departments released the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)," aiming to optimize the structure and upgrade the traditional Chinese medicine industry [5]. - By 2030, a collaborative development system for the entire traditional Chinese medicine industry chain is expected to take shape, with significant improvements in quality and efficiency [5]. - The plan includes six key tasks with 15 specific actions, such as enhancing raw material quality, promoting collaborative innovation, and modernizing the national medicine industry [5]. Performance Recovery - The report indicates a performance recovery trend in the traditional Chinese medicine sector, with companies like Teva Pharmaceutical expecting a net profit of 70 million to 90 million yuan in 2025, representing a year-on-year increase of 241.55% to 339.13% [5]. - Yiling Pharmaceutical forecasts a turnaround with a net profit of 1.2 billion to 1.3 billion yuan, compared to a loss of 725 million yuan in 2024 [5]. - Other companies, such as Huaren Jiangzhong and Zhongsheng Pharmaceutical, also project significant profit increases for 2025, indicating a positive outlook for the sector [5]. Investment Recommendations - The report suggests that the traditional Chinese medicine industry is likely to continue its transformation and upgrade, with improved resilience and stability in the supply chain [6]. - It recommends focusing on companies such as Zhongsheng Pharmaceutical, Teva Pharmaceutical, Yiling Pharmaceutical, and Huaren Jiangzhong as potential investment opportunities [6].

Core Viewpoint - On February 25, 2025, Kewah Pharmaceutical's stock increased by 0.43%, with a trading volume of 30.14 million yuan. The company experienced a net financing outflow of 680,200 yuan on that day, indicating a low financing balance relative to its market value [1]. Financing Summary - Kewah Pharmaceutical had a financing buy-in of 3.40 million yuan on February 25, with a current financing balance of 128 million yuan, accounting for 1.56% of its circulating market value. This financing balance is below the 10th percentile level over the past year, indicating a low position [1]. - In terms of securities lending, the company repaid 2,500 shares and sold 500 shares on February 25, with a selling amount of 7,045 yuan. The current securities lending balance is 2.18 million yuan, which exceeds the 90th percentile level over the past year, indicating a high position [1]. Financial Performance - As of December 31, 2025, Kewah Pharmaceutical reported a revenue of 1.684 billion yuan for the first nine months, a year-on-year decrease of 43.24%. The net profit attributable to shareholders was -33.54 million yuan, a year-on-year decrease of 105.72% [2]. - Cumulatively, since its A-share listing, Kewah Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, Kewah Pharmaceutical had 48,000 shareholders, a decrease of 2.04% from the previous period. The average circulating shares per person increased by 2.08% to 12,166 shares [2]. - Among the top ten circulating shareholders, E Fund CSI Dividend ETF (515180) is the fifth largest, holding 3.4008 million shares, an increase of 239,600 shares from the previous period. Hong Kong Central Clearing Limited is the seventh largest, holding 2.8412 million shares, a decrease of 128,700 shares [3].

Core Viewpoint - Shandong Keyuan Pharmaceutical Co., Ltd. has significantly revised its 2025 profit forecast, expecting a net profit decline of 70%-80% due to an unexpected legal dispute involving its subsidiary [1][2] Group 1: Profit Forecast Revision - The company revised its expected net profit from a previous estimate of 27.20 million to 39.29 million yuan (a decline of 35%-55%) to a new range of 12.09 million to 18.13 million yuan (a decline of 70%-80%) [1][2] - The legal dispute involves a compensation of 16.11 million yuan that will be recognized as an extraordinary expense, impacting the net profit [1][2] Group 2: Legal and Financial Implications - The subsidiary, Shandong Linuo Pharmaceutical Co., Ltd., has had some bank accounts frozen due to the legal dispute, with 57 million yuan frozen, representing 4.19% of the company's latest audited net assets [2] - The ongoing legal issues have the potential to affect the normal operations of the subsidiary [2] Group 3: Historical Performance and Challenges - In 2023, the company reported a revenue of 448 million yuan, a slight increase of 1.07%, but net profit decreased by 15.60% to 77.04 million yuan [2] - For 2024, revenue grew by 3.60% to 464 million yuan, but net profit fell to 60.45 million yuan, a decline of 21.54% [2] - The first three quarters of 2025 showed continued deterioration, with revenue at 303 million yuan (down 8.5%) and net profit at 31.47 million yuan (down 20.7%) [2] Group 4: Strategic Moves and Acquisitions - The company attempted to find new growth through acquisitions, planning to acquire 99.42% of Hongjitang for up to 3.581 billion yuan, which was seen as a significant asset restructuring [3][4] - The acquisition was expected to enhance the company's business by integrating traditional Chinese medicine with chemical pharmaceuticals, aiming for cost reduction and improved operational efficiency [4] Group 5: Termination of Acquisition - On November 28, the company decided to terminate the acquisition due to changes in the overall market environment, which were not elaborated upon [5] - The acquisition price was deemed excessively high, equating to 7.7 times the company's 2024 revenue and 59 times its net profit, far exceeding its capital capacity [5]

Group 1 - The core viewpoint of the article is that the company has established a strategic reserve mechanism for commonly used Chinese medicinal materials to mitigate market volatility risks [1] - The company sources its Chinese medicinal materials from authentic medicinal material bases for its own production of Chinese medicinal slices and proprietary Chinese medicines [1] - The strategic reserve mechanism is designed to effectively reduce the impact of price fluctuations in Chinese medicinal materials on the company's operations [1]

Group 1 - Southbound funds increased their holdings in China Traditional Chinese Medicine (00570.HK) by 264,000 shares on February 23 [1] - Over the past five trading days, there were three days of net reductions in southbound fund holdings, totaling a net decrease of 15.602 million shares [1] - In the last 20 trading days, there were ten days of net increases in southbound fund holdings, with a total net increase of 19.712 million shares [1] - Currently, southbound funds hold 1.612 billion shares of China Traditional Chinese Medicine, accounting for 32.0% of the company's issued ordinary shares [1] Group 2 - China Traditional Chinese Medicine Holdings Limited primarily engages in the manufacturing and sales of traditional Chinese medicine [2] - The company operates through four divisions, focusing on the production and sales of traditional Chinese medicine formula granules, health products, and traditional Chinese medicine slices [2] - The Tianjiang division also provides healthcare solutions related to traditional Chinese medicine through offline medical institutions, including consultations and prescriptions [2] - The Tongjitang division is involved in the production and sales of traditional Chinese medicine formula granules, slices, and proprietary Chinese medicines, as well as various health products [2]

Core Viewpoint - Chongqing Weier Kangqi Hui Pharmaceutical Co., Ltd. has been found to have safety hazards, leading to a suspension of sales as a risk control measure by the Chongqing Drug Administration [2] Company Summary - Company Name: Chongqing Weier Kangqi Hui Pharmaceutical Co., Ltd. [2] - License Number: 渝AA0230793 [2] - Business Address: No. 827, Section 33, Erhuan South Road, Tangxiang Street, Dazhu District, Chongqing [2] - Warehouse Address: No. 827, Section 33, Erhuan South Road, Tangxiang Street, Dazhu District, Chongqing, covering multiple floors [2] - Business Scope: Includes chemical raw materials and their preparations, antibiotic raw materials and their preparations, biochemical products, traditional Chinese medicine, Chinese medicinal materials, Chinese medicinal pieces, biological products, protein anabolic agents, and peptide hormones [2] Regulatory Actions - The Chongqing Drug Administration has implemented a sales suspension for the company due to identified safety hazards [2] - The company is required to strictly fulfill its primary responsibility to eliminate quality safety hazards and submit a rectification report to the Chongqing Drug Administration [2] - The risk control measures will be lifted only after a re-inspection confirms compliance with the necessary conditions [2]